4. FDA. Leukeran (Chlorambucil) Prescribing Information. 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
5. Kementerian Kesehatan. Klorambusil. In: Formularium Nasional. Kementerian Kesehatan. 2017. http://farmalkes.kemkes.go.id/en/2018/02/formularium-nasional-2017/
6. MIMS. Chlorambucil. 2022. https://www.mims.com/indonesia/drug/info/chlorambucil?mtype=generic
8. Drugs.com. Chlorambucil. 2022. https://www.drugs.com/monograph/chlorambucil.html
13. Cancerresearchuk.org. Chlorambucil (Leukeran). 2022. https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/chlorambucil
14. Boyiadzis, M. Hemato-Oncology Therapy 2nd Edition. McGraw-Hill Education. 2014.
15. Medscape. Chlorambucil : Dosing & Uses. 2022. https://reference.medscape.com/drug/leukeran-chlorambucil-342112
16. Buske C, Leblond V. How to manage Waldenstrom's macroglobulinemia. Leukemia. 2013;27(4):762–772. doi:10.1038/leu.2013.36
17. Dimopoulos MA, Kastritis E, Owen RG, et al. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014;124(9):1404–1411. doi:10.1182/blood-2014-03-565135
18. Chen CI. Treatment For Waldenstrom's Macroglobulinemia. Annals of Oncology, Volume 15, Issue 4, April 2004; 550-58. https://doi.org/10.1093/annonc/mdh128
19. Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol. 2015 Aug;63(2):503-14.
23. Pratt G, El-Sharkawi D, Kothari J, D'Sa S, Auer R, McCarthy H, Krishna R, Miles O, Kyriakou C, Owen R. Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline. Br J Haematol. 2022 Apr;197(2):171-187.